Cantor Fitzgerald Weighs in on DNLI FY2025 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Denali Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($2.86) per share for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share.

DNLI has been the topic of a number of other reports. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target on the stock in a report on Monday, December 16th. Robert W. Baird began coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an “outperform” rating and a $31.00 target price on the stock. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Jefferies Financial Group increased their price target on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Finally, HC Wainwright cut their price objective on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Trading Up 1.2 %

Denali Therapeutics stock opened at $23.31 on Wednesday. The firm has a market cap of $3.35 billion, a PE ratio of -8.45 and a beta of 1.39. The stock’s 50 day simple moving average is $22.68 and its two-hundred day simple moving average is $24.80. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the previous year, the firm posted ($0.72) earnings per share.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of DNLI. FMR LLC grew its stake in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock valued at $228,128,000 after buying an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Denali Therapeutics by 63.2% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Denali Therapeutics in the second quarter worth approximately $24,454,000. Wellington Management Group LLP increased its stake in Denali Therapeutics by 9.2% during the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock worth $312,491,000 after acquiring an additional 903,683 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in Denali Therapeutics by 12.7% during the second quarter. Marshall Wace LLP now owns 2,418,833 shares of the company’s stock worth $56,165,000 after acquiring an additional 272,454 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Vicki L. Sato sold 1,020 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now directly owns 111,056 shares in the company, valued at $3,331,680. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,518 shares of company stock valued at $1,469,382. Corporate insiders own 7.90% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.